0000880771-16-000210.txt : 20161115
0000880771-16-000210.hdr.sgml : 20161115
20161115161742
ACCESSION NUMBER: 0000880771-16-000210
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161111
FILED AS OF DATE: 20161115
DATE AS OF CHANGE: 20161115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161999888
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2016-11-11
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2016-11-11
4
M
0
5301
1.81
A
92085
D
Common Stock
2016-11-11
4
S
0
5301
10.0078
D
86784
D
Common Stock
2016-11-14
4
M
0
24699
1.81
A
111483
D
Common Stock
2016-11-14
4
S
0
24699
10.3278
D
86784
D
Non-Qualified Stock Option (right to buy)
1.81
2016-11-11
4
M
0
5301
0
D
2018-03-18
Common Stock
5301
204699
D
Non-Qualified Stock Option (right to buy)
1.81
2016-11-14
4
M
0
24699
0
D
2018-03-18
Common Stock
24699
180000
D
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
Includes 404 shares purchased under the Issuer's Employee Stock Purchase Plan on August 31, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
1/36th of such shares will vest on June 1, 2010 and 1/36th will vest monthly thereafter over a three-year period, provided the reporting person remains employed by the Company.
/s/ Friedhelm Blobel
2016-11-15